Navigation Links
NRI Doctor's R&D Model in India to Slash Cost of Drugs

A British doctor of Indian origin and his colleague are set to drastically lower the cost of medicines //and pose a challenge to the monopoly of multinational drug companies.

Sunil Shaunak, professor of infectious diseases at Imperial College, London, and Steve Brocchini from the London School of Pharmacy are leading clinical trials in India for a drug for hepatitis C.

The two academics have devised a way to invent new medicines and get them to market at a fraction of the cost charged by big drug companies. Their model is likely to enable millions in poor countries to be cured of infectious diseases and reduce the drugs bill of Britain's National Health Service.

The Guardian reported Tuesday that Shaunak called their revolutionary new model "ethical pharmaceuticals". Improvements devised to the molecular structure of an existing, expensive drug turned it technically into a new medicine, which was no longer under a 20-year patent to a multinational drug company and could be made and sold cheaply.

"The process has the potential to undermine the monopoly of the big drug companies and bring cheaper drugs not only to poor countries but back to the UK," the newspaper reported.

It added that Shaunak and Brocchini had linked up with an unnamed Indian biotech company, which will manufacture the first drug - for hepatitis C - if clinical trials in India are successful. The report added that the trials are sponsored by the Indian government.

Hepatitis C reportedly affects 170 million people worldwide and at least 200,000 in Britain.

Multinational drug companies put the cost of the research and development of a new drug at $800 million. According to Shaunak and Brocchini, the cost of developing their drug will be only a few million pounds.

The report added that Imperial College would hold the patent on the hepatitis C drug to prevent anybody attempting to block its development. The college employs top patent lawyers who also work for some of the big pharmaceutical companies.

"Once the drugs have passed through clinical trials and have been licensed in India, the same data could be used to obtain a European licence so that they could be sold to the NHS as well," the report said.

Shaunak told the newspaper that it was time that the monopoly on drug invention and production by multinational corporations - which charge high prices because they need to make big profits for their shareholders - was broken.

"The pharmaceutical industry has convinced us that we have to spend billions of pounds to invent each drug. We have spent a few millions. Yes, it will be a threat to the monopoly that there is.

"I'm not only an inventor of medicines - I'm an end user. We have become so completely dependent on the big pharmaceutical industry to provide all the medicines we use. Why should we be completely dependent on them when we do all the creative stuff in the universities?

"Maybe the time has come to say why can't somebody else do it? What we have been struck by is that once we have started to do it, it is not so difficult."

The team's work on the hepatitis C drug is supported by a grant from the Wellcome Trust and help and advice from the Department for Trade and Industry and the Foreign and Commonwealth Office.

The report added that the "ethical pharmaceutical" model was unlikely to find much favour with the multinational pharmaceutical companies, which already employed large teams of lawyers to defend the patents which they describe as the lifeblood of the industry.

Source-Newswise
'"/>




Related medicine news :

1. Kiwi veterinarians angry Over Doctors Advice
2. Doctors strike called off in Maharashtra
3. Doctors AIDS Documentary Focus on Stigma and Discrimination
4. Researchers Develop Mouse Model Of Brain Tumor
5. New Model for understanding Tumor Metastasis
6. Mathematical Model Can Now Help Predict Asthma Risk
7. Model Kate Moss - Re-Birth After Humiliation
8. Womens Self-Esteem Not Lowered By Seeing Ultra Thin Models
9. India Can Become A Role Model In Combating HIV Infections
10. Mouse Models To Determine The Cause Of Aggressive Leukemia
11. Aussie Model Macpherson Hated Tall Figure
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... 22, 2017 , ... Egg freezing and embryo freezing are ... a slight statistical advantage for live births, frozen eggs offer many advantages, depending ... undergoing medical treatment or who are concerned about the decline of their fertility ...
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery ... is pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as one ... is an annual award that was started in 2003 to salute young achievers in ...
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction ... Services for professionals in the addiction treatment industry entitled: Special Investigations Unit ... Insurance companies and state and federal governments are increasingly scrutinizing the addiction treatment ...
(Date:9/21/2017)... ... 21, 2017 , ... Demonstrating a consistent and continued commitment ... been awarded five-year accreditation status through the Public Health Accreditation Board ... by a PHAB-accredited health department now extend to more than 203 million people, ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in Chicago, ... the life-sciences industry for ensuring label quality and improving patient safety. , ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... 5, 2017 Sapheneia and Scannerside received FDA ... DoseCheck is a third-party Vendor neutral CT product that ... allows compliance with current MITA standards. ... DoseCheck solution is specifically designed to provide CT operators, ... radiation doses over a predefined threshold. Scannerside Dose Check ...
(Date:9/1/2017)... PALMER, Mass. , Sept. 1, 2017 ... Complete HealthCare Solutions, Inc , highlights opportunities for growth ... Street Journal report that Marlin Equity is seeking a ... is an annual award-winning 22-year-old healthcare solutions Value Added ... market.  "As the ...
(Date:8/29/2017)... , Aug. 29, 2017 In a ... security, and regulatory compliance for veterinary practices of all ... a new partnership that makes TITAN,s expertise in physical ... available to Cubex,s clients nationally. ... buying and handling controlled substances is at risk today," ...
Breaking Medicine Technology: